Skip to main content
Equibles
MDXG logo

MDXG · Mimedx Group, Inc. · Webcasts, Transcripts & Audio

Track MDXG — free

Use MDXG with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research MDXG.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$4.62 +0.07 (+1.54%) At close · Oct 6
Russell 2000 member Rebalance outlook locked
Customer concentration — top 10 customers 22% of revenue

10 customers — 22% of revenue (the year ended December 31, 2025)

“For the years ended December 31, 2025, 2024, and 2023, our top ten customers accounted for 22%, 20% and 20%, respectively, of our net sales”

Key customers — 1% of revenue (the year ended December 31, 2025)

“net sales to all U.S. government accounts comprised approximately 1%, 1% and 2%, respectively, of our net sales.”

10 customers — 20% of revenue (the year ended December 31, 2024)

“For the years ended December 31, 2025, 2024, and 2023, our top ten customers accounted for 22%, 20% and 20%, respectively, of our net sales”

Key customers — 1% of revenue (the year ended December 31, 2024)

“net sales to all U.S. government accounts comprised approximately 1%, 1% and 2%, respectively, of our net sales.”

10 customers — 20% of revenue (the year ended December 31, 2023)

“For the years ended December 31, 2025, 2024, and 2023, our top ten customers accounted for 22%, 20% and 20%, respectively, of our net sales”

Key customers — 2% of revenue (the year ended December 31, 2023)

“net sales to all U.S. government accounts comprised approximately 1%, 1% and 2%, respectively, of our net sales.”
View the 10-K filed Feb 25, 2026
Market Cap
$680.70M
Shares
145.76M
Volume · Oct 6 1.05M Avg daily vol (3M) 1.24M

Mimedx Group, Inc. Webcasts

Earnings calls, investor updates, investor days and conferences for Mimedx Group, Inc. (MDXG), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.

Pull transcripts and briefs through the earnings call transcript API or MCP →

Revenue & result across quarters

Revenue Net income YoY up YoY down artefacts
▲7.3% $67.69M −$8.43M '22 Q3 22-11-02 ▲46.4% $74.38M −$414,000 '22 Q4 23-01-09 ▲21.7% $71.68M −$4.98M '23 Q1 23-05-02 ▲21.5% $81.26M $1.20M '23 Q2 23-08-01 ▲20.7% $81.71M $8.53M '23 Q3 23-10-30 ▲16.7% $86.83M $53.48M '23 Q4 24-02-28 ▲18.2% $84.71M $9.26M '24 Q1 24-04-30 ▲7.3% $87.21M $17.62M '24 Q2 24-07-31 ▲2.9% $84.06M $8.10M '24 Q3 24-10-30 ▲7% $92.91M $7.44M '24 Q4 25-02-26 ▲4.1% $88.20M $7.02M '25 Q1 25-04-30 ▲13.1% $98.61M $9.62M '25 Q2 25-07-30 ▲35.3% $113.72M $16.75M '25 Q3 25-10-29 ▲27.1% $118.09M $15.19M '25 Q4 26-02-25 ▼33.1% $58.99M −$10.86M '26 Q1 26-04-29 LATEST ▼34.7% $64.36M −$14.84M '26 Q2 26-07-29
Earnings call
FY26 · Q2
2026-07-29
Mimedx Group, Inc. (MDXG) Q2 2026 Earnings Call Transcript
Confident tone Profitability and cost actions Wound care reimbursement headwinds Product launches and 510(k) submissions
Revenue
$64.36M
▼ 34.7% YoY
Diluted EPS
$-0.10
▼ 266.7% YoY
Gross margin
69.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY26 · Q1
2026-04-29
Mimedx Group, Inc. (MDXG) Q1 2026 Earnings Call Transcript
Cautious tone Wound care market disruption Surgical business growth Regulatory and reimbursement issues
Revenue
$58.99M
▼ 33.1% YoY
Diluted EPS
$-0.07
▼ 240% YoY
Gross margin
70.6%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-02-25
Mimedx Group, Inc. (MDXG) Q4 2025 Earnings Call Transcript
Positive tone Surgical business growth and momentum Clinical research and evidence generation Financial results and cash position
Revenue
$118.09M*
▲ 27.1% YoY
Gross margin
83.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-10-29
Mimedx Group, Inc. (MDXG) Q3 2025 Earnings Call Transcript
Confident tone Quarterly financial performance Product portfolio expansion Medicare LCD / reimbursement reform
Revenue
$113.72M
▲ 35.3% YoY
Diluted EPS
$0.11
▲ 120% YoY
Gross margin
83.5%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-07-30
Mimedx Group, Inc. (MDXG) Q2 2025 Earnings Call Transcript
Confident tone Medicare reimbursement reform Product portfolio expansion LCDs and clinical evidence requirements
Revenue
$98.61M
▲ 13.1% YoY
Diluted EPS
$0.06
▼ 50% YoY
Gross margin
81.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-04-30
Mimedx Group, Inc. (MDXG) Q1 2025 Earnings Call Transcript
Positive tone Medicare LCD and reimbursement disruption Financial performance and cash position Surgical business growth
Revenue
$88.20M
▲ 4.1% YoY
Diluted EPS
$0.05
▼ 16.7% YoY
Gross margin
81.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-02-26
Mimedx Group, Inc. (MDXG) Q4 2024 Earnings Call Transcript
Confident tone Product portfolio innovation and launches Revenue growth and financial performance Regulatory and legal matters
Revenue
$92.91M*
▲ 7% YoY
Gross margin
81.8%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-10-30
Mimedx Group, Inc. (MDXG) Q3 2024 Earnings Call Transcript
Confident tone HELIOGEN launch progress Product portfolio expansion Reimbursement fraud / Medicare headwinds
Revenue
$84.06M
▲ 2.9% YoY
Diluted EPS
$0.05
▼ 16.7% YoY
Gross margin
81.8%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-07-31
Mimedx Group, Inc. (MDXG) Q2 2024 Earnings Call Transcript
Positive tone Top-line growth and quarterly financials HELIOGEN xenograft launch and opportunity Product portfolio innovation (AMNIOEFFECT, EPIEFFECT)
Revenue
$87.21M
▲ 7.3% YoY
Diluted EPS
$0.12
▲ 1100% YoY
Gross margin
83.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-04-30
Mimedx Group, Inc. (MDXG) Q1 2024 Earnings Call Transcript
Confident tone Product portfolio expansion and innovation Wound & Surgical market growth and new launches Revenue growth and Q1 financial performance
Revenue
$84.71M
▲ 18.2% YoY
Diluted EPS
$0.06
Gross margin
84.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-02-28
Mimedx Group, Inc. (MDXG) Q4 2023 Earnings Call Transcript
Confident tone Financial Performance & Growth EPIEFFECT Product Launch Balance Sheet & Cash Generation
Revenue
$86.83M*
▲ 16.7% YoY
Gross margin
84.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-10-30
Mimedx Group, Inc. (MDXG) Q3 2023 Earnings Call Transcript
Revenue
$81.71M
▲ 20.7% YoY
Diluted EPS
$0.06
Gross margin
81.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-08-01
Mimedx Group, Inc. (MDXG) Q2 2023 Earnings Call Transcript
Revenue
$81.26M
▲ 21.5% YoY
Diluted EPS
$0.01
Gross margin
83.3%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-05-02
Mimedx Group, Inc. (MDXG) Q1 2023 Earnings Call Transcript
Revenue
$71.68M
▲ 21.7% YoY
Diluted EPS
$-0.06
Gross margin
82.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-01-09
Mimedx Group, Inc. (MDXG) Q4 2022 Earnings Call Transcript
Revenue
$74.38M*
▲ 46.4% YoY
Gross margin
80.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-11-02
Mimedx Group, Inc. (MDXG) Q3 2022 Earnings Call Transcript
Revenue
$67.69M
▲ 7.3% YoY
Diluted EPS
$-0.09
Gross margin
82.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-08-02
Mimedx Group, Inc. (MDXG) Q2 2022 Earnings Call Transcript
Revenue
$66.88M
▼ 1.9% YoY
Diluted EPS
$-0.11
Gross margin
82.3%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-05-03
Mimedx Group, Inc. (MDXG) Q1 2022 Earnings Call Transcript
Revenue
$58.89M
▼ 1.8% YoY
Diluted EPS
$-0.11
Gross margin
83.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-01-10
Mimedx Group, Inc. (MDXG) Q4 2021 Earnings Call Transcript
Revenue
$50.81M*
▼ 25.9% YoY
Gross margin
86.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-11-02
Mimedx Group, Inc. (MDXG) Q3 2021 Earnings Call Transcript
Revenue
$63.07M
▼ 1.9% YoY
Diluted EPS
$-0.04
Gross margin
83.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-08-03
Mimedx Group, Inc. (MDXG) Q2 2021 Earnings Call Transcript
Revenue
$68.17M
▲ 27.1% YoY
Diluted EPS
$-0.03
Gross margin
81.3%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q1
2021-04-28
Mimedx Group, Inc. (MDXG) Q1 2021 Earnings Call Transcript
Revenue
$59.97M
▼ 2.9% YoY
Diluted EPS
$-0.09
Gross margin
83.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q4
2021-03-09
Mimedx Group, Inc. (MDXG) Q4 2020 Earnings Call Transcript
Revenue
$68.55M
▼ 10.3% YoY
Diluted EPS
$-0.17
Gross margin
84.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY20 · Q3
2020-11-04
Mimedx Group, Inc. (MDXG) Q3 2020 Earnings Call Transcript
Revenue
$64.30M
▼ 27.6% YoY
Diluted EPS
$-0.48
▼ 536.4% YoY
Gross margin
84.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q2
2020-08-04
Mimedx Group, Inc. (MDXG) Q2 2020 Earnings Call Transcript
Revenue
$53.65M
▼ 20.4% YoY
Diluted EPS
$-0.08
Gross margin
84.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Showing 1–25 of 25 webcasts
Key facts CIK 1376339 CUSIP 602496101 13F (30d) 10 filings 6 filers Visit website Investor relations